Mundipharma announces licence extension submission for Invokana and Vokanamet to EMA

This article was originally published here

The submission is based on the results from the landmark Phase III CREDENCE study1 which evaluated the efficacy and safety of canagliflozin versus placebo in this high-risk patient

The post Mundipharma announces licence extension submission for Invokana and Vokanamet to EMA appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply